Aglaia Oncology Funds

What is Aglaia Oncology Funds?

Aglaia Oncology Funds is a private equity firm specializing in investments within the biotech and medical devices industries. Their expertise lies in equity, particularly with a focus on MBO/LBO and restructuring scenarios.

The firm operates from its headquarters at 2 Bethesda Metro Center, Suite 1510, Bethesda, Maryland, 20814, United States.

Aglaia Oncology Funds aims to leverage its deep vertical expertise, cultivated through years of industry-specific experience, to identify and invest in lower middle market niche leaders that demonstrate significant growth potential within the healthcare and business services sectors.

They believe in a hands-on approach, seeking to add value through strategic guidance and by fostering strong partnerships with the executive teams of their portfolio companies.

The firm prides itself on its network of relationships with executives across sub-verticals, which facilitates familiarity with sector competitors and reaffirms the firm’s reputation as both prudent investors and responsible stewards of the companies they invest in. Aglaia Oncology Funds’ investment strategy underlines the importance of organic growth, complemented by mergers and acquisitions to drive expansion and diversification.

The company’s portfolio showcases a range of entities in various healthcare and business service niches, from medical supply chain management providers to specialized consultancy services for the pharmaceutical and biotech sectors. In addition to financial investment, they emphasize incorporating environmental, social, and governance policies, along with Diversity, Equity, and Inclusion initiatives into their operations and investment decisions.

Their comprehensive corporate responsibility approach reflects a commitment to more than just financial success, seeking to ensure a positive impact on society and the environment while delivering satisfactory returns to stakeholders.